Biotech Values

[ghmm]

ITMN:

IMO Roche will advance the compound and the data will determine if it goes on or not. I think its still premature to right off the compound. 175M is a fair chunk of money (that is more then Achillion's market cap and 2/3 Idenix's) and probably represents fair value not just "go away" money. I do agree that Roche probably didn't care for the exclusivity and if they do a future deal will likely not have that language. But I think they could have gotten out of the contract with Danoprevir returning it to InterMune so it leads me to think they want to at least see what the future holds. Plus I think it may have only been another year or two to go on the exclusivity. Who knows the INFORM series could end up adding another compound (outside of ritonavir) or perhaps PEG/Riba in INFORM ends up producing outstanding results with good tolerabilty and Roche moves in that direction?

That being said if Roche announces a partnership deal in the next couple months then I will concede the death of 191 and this was go away money .